PatientSpotlight, by PanaceaIntelPatientSpotlight

Topic · Immunology

Regulatory

Coverage of FDA, EMA, MHRA, NICE, and other regulatory action across the therapy areas we follow - approvals, pathway choices, and the recalibrated bar each new precedent sets. 1 piece on regulatory in Immunology, newest first within each collection.

← All topics
FilterAll (32)Oncology (5)Rare Disease (7)Immunology (1)Neurology (14)Cardiometabolic (1)Women's Health (1)Mental Health (3)

Signals

1
SignalApr 26, 2026FDA · EMA · peer-reviewed

JAK class label restrictions are reshaping moderate-disease prescribing

FDA boxed warnings and EMA caution have repositioned JAK inhibitors as later-line agents in rheumatoid arthritis, atopic dermatitis, and psoriatic arthritis - reshaping the practical sequencing decision in moderate disease.

TreatmentRegulatorySafetyAccess